Protagonist Therapeutics Inc (NASDAQ:PTGX) – Equities researchers at Leerink Swann lowered their FY2018 earnings per share (EPS) estimates for shares of Protagonist Therapeutics in a research note issued on Wednesday, November 7th. Leerink Swann analyst J. Schwartz now anticipates that the company will post earnings per share of ($1.84) for the year, down from their previous forecast of ($1.28). Leerink Swann currently has a “Outperform” rating and a $21.00 target price on the stock. Leerink Swann also issued estimates for Protagonist Therapeutics’ Q4 2018 earnings at ($0.67) EPS, FY2019 earnings at ($2.60) EPS and FY2020 earnings at ($2.01) EPS.
Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Tuesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). The business had revenue of $6.12 million during the quarter, compared to analysts’ expectations of $6.35 million. Protagonist Therapeutics had a negative net margin of 70.54% and a negative return on equity of 24.59%.
PTGX opened at $9.70 on Friday. The firm has a market capitalization of $209.30 million, a PE ratio of -4.64 and a beta of 3.44. Protagonist Therapeutics has a 12-month low of $5.50 and a 12-month high of $23.97.
A number of hedge funds have recently bought and sold shares of PTGX. Schwab Charles Investment Management Inc. grew its holdings in shares of Protagonist Therapeutics by 67.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 32,315 shares of the company’s stock worth $278,000 after purchasing an additional 13,015 shares during the period. BlackRock Inc. grew its holdings in shares of Protagonist Therapeutics by 39.0% during the 1st quarter. BlackRock Inc. now owns 687,160 shares of the company’s stock worth $5,904,000 after purchasing an additional 192,632 shares during the period. Cubist Systematic Strategies LLC grew its holdings in shares of Protagonist Therapeutics by 255.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 11,593 shares of the company’s stock worth $100,000 after purchasing an additional 8,327 shares during the period. Millennium Management LLC grew its holdings in shares of Protagonist Therapeutics by 66.4% during the 1st quarter. Millennium Management LLC now owns 320,739 shares of the company’s stock worth $2,755,000 after purchasing an additional 128,009 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in shares of Protagonist Therapeutics by 303.3% during the 2nd quarter. Acadian Asset Management LLC now owns 233,830 shares of the company’s stock worth $1,572,000 after purchasing an additional 175,849 shares during the period. Hedge funds and other institutional investors own 57.34% of the company’s stock.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Featured Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.